{"PubmedArticle": [{"MedlineCitation": {"OtherID": [], "SpaceFlightMission": [], "KeywordList": [], "CitationSubset": ["IM"], "InvestigatorList": [], "OtherAbstract": [], "GeneralNote": [], "PMID": "25097972", "DateCompleted": {"Year": "2014", "Month": "09", "Day": "02"}, "DateRevised": {"Year": "2016", "Month": "10", "Day": "18"}, "Article": {"Language": ["rus"], "ArticleDate": [], "ELocationID": [], "Journal": {"ISSN": "0023-2130", "JournalIssue": {"Issue": "4", "PubDate": {"Year": "2014", "Month": "Apr"}}, "Title": "Klinichna khirurhiia", "ISOAbbreviation": "Klin Khir"}, "ArticleTitle": "[Impact of a combined application of ozonized perftoran and glutoxim on the immune status of the patients and the cytokines profile in extended peritonitis].", "Pagination": {"StartPage": "27", "EndPage": "29", "MedlinePgn": "27-9"}, "Abstract": {"AbstractText": ["The immune status was studied while surgical treatment of 74 patients, suffering extended peritonitis (EP). In 38 patients (group of comparison) a complex routine therapy was conducted, in 36 (the main group)--along with routine complex measures of treatment a local and systemic ozonotherapy, using ozonized perftoran (OP) and glutoxim (for immunocorrection), were applied. The patients severity state was estimated in accordance to the Mahnheim's peritoneal index. In all the patients while hospitalization there were revealed changes in T--and B--links of immunity, in phagocytosis and the cytokins profile, significant of which have depended upon the EP severity. The combined local and systemic application of OP and glutoxim in complex of conservative treatment is pathogenetically substantiated, it permits more rapidly to eliminate the immunity disorders and the cytokines balance, as well as inflammatory process in abdominal cavity and to improve the results of surgical treatment significantly."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [], "LastName": "Abdullaev", "ForeName": "I A", "Initials": "IA"}], "PublicationTypeList": ["English Abstract", "Journal Article"]}, "MedlineJournalInfo": {"Country": "Ukraine", "MedlineTA": "Klin Khir", "NlmUniqueID": "9516872", "ISSNLinking": "0023-2130"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Blood Substitutes"}, {"RegistryNumber": "0", "NameOfSubstance": "Fluorocarbons"}, {"RegistryNumber": "0", "NameOfSubstance": "IL4 protein, human"}, {"RegistryNumber": "0", "NameOfSubstance": "Immunologic Factors"}, {"RegistryNumber": "0", "NameOfSubstance": "Interleukin-8"}, {"RegistryNumber": "0", "NameOfSubstance": "Oligopeptides"}, {"RegistryNumber": "0", "NameOfSubstance": "Tumor Necrosis Factor-alpha"}, {"RegistryNumber": "0", "NameOfSubstance": "glutoxim"}, {"RegistryNumber": "207137-56-2", "NameOfSubstance": "Interleukin-4"}, {"RegistryNumber": "66H7ZZK23N", "NameOfSubstance": "Ozone"}, {"RegistryNumber": "99752-82-6", "NameOfSubstance": "perftoran"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Adolescent"}, {"QualifierName": [], "DescriptorName": "Adult"}, {"QualifierName": [], "DescriptorName": "Aged"}, {"QualifierName": ["drug effects", "immunology", "pathology"], "DescriptorName": "B-Lymphocytes"}, {"QualifierName": ["therapeutic use"], "DescriptorName": "Blood Substitutes"}, {"QualifierName": [], "DescriptorName": "Case-Control Studies"}, {"QualifierName": [], "DescriptorName": "Drug Therapy, Combination"}, {"QualifierName": [], "DescriptorName": "Female"}, {"QualifierName": ["therapeutic use"], "DescriptorName": "Fluorocarbons"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["drug effects"], "DescriptorName": "Immunity, Innate"}, {"QualifierName": ["therapeutic use"], "DescriptorName": "Immunologic Factors"}, {"QualifierName": ["biosynthesis", "immunology"], "DescriptorName": "Interleukin-4"}, {"QualifierName": ["biosynthesis", "immunology"], "DescriptorName": "Interleukin-8"}, {"QualifierName": [], "DescriptorName": "Male"}, {"QualifierName": [], "DescriptorName": "Middle Aged"}, {"QualifierName": ["therapeutic use"], "DescriptorName": "Oligopeptides"}, {"QualifierName": ["therapeutic use"], "DescriptorName": "Ozone"}, {"QualifierName": ["drug therapy", "immunology", "pathology"], "DescriptorName": "Peritonitis"}, {"QualifierName": [], "DescriptorName": "Severity of Illness Index"}, {"QualifierName": ["drug effects", "immunology", "pathology"], "DescriptorName": "T-Lymphocytes"}, {"QualifierName": ["biosynthesis", "immunology"], "DescriptorName": "Tumor Necrosis Factor-alpha"}]}, "PubmedData": {"ReferenceList": [], "History": [{"Year": "2014", "Month": "8", "Day": "8", "Hour": "6", "Minute": "0"}, {"Year": "2014", "Month": "8", "Day": "8", "Hour": "6", "Minute": "0"}, {"Year": "2014", "Month": "9", "Day": "3", "Hour": "6", "Minute": "0"}], "PublicationStatus": "ppublish", "ArticleIdList": ["25097972"]}}], "PubmedBookArticle": []}